Kai Vogtländer

Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry

Keith A.A. Fox, Victor Aboyans, E. Sebastian Debus et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 2022 · 29 citations

Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study

Catriona N. Grant, Marco Serrani, Kai Vogtländer et al. · International Journal of Women s Health · 2016 · 26 citations · Full text

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH

Henning Gall, Jean‐Luc Vachiéry, Nobuhiro Tanabe et al. · Lung · 2018 · 24 citations · Full text

Risk of Hypersensitivity Reactions to Iopromide After Intra-Arterial Versus Intravenous Administration

Jan Endrikat, Alexander Michel, Ralf Kölbach et al. · Investigative Radiology · 2019 · 24 citations · Full text

Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both

Keith A.A. Fox, Sonia S. Anand, Victor Aboyans et al. · American Heart Journal · 2020 · 20 citations

Thrombosis, Acetylsalicylic Acid, Cardiovascular Disease +10